2 results
Approved WMOWill not start
Part 1 - To determine the efficacy of oral BCX9930 monotherapy administered for 24 weeks, compared to continued complement component 5 (C5) inhibitor therapy, in subjects with paroxysmal nocturnal hemoglobinuria (PNH) with an inadequate response to…
Approved WMORecruiting
Dose Escalation Objectives:Primary:* Determine maximum tolerated dose (MTD) and RP2DSecondary:* Establish tolerability of epcoritamab* Establish pharmacokinetic (PK) profile after single and multiple doses* Evaluate immunogenicity* Evaluate anti-…